Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **dopaminergic neuron terminal** is the specialized axonal ending of a neuron that synthesizes, stores, and releases the neurotransmitter dopamine into the synaptic cleft in response to electrical impulses[3][6]. These terminals contain key proteins for dopamine metabolism, including the dopamine transporter (DAT) for reuptake, vesicular monoamine transporters for storage, and enzymes such as tyrosine hydroxylase for synthesis[3][6]. They are functionally critical in multiple brain pathways that regulate movement, emotion, motivation, and cognition[2][3][6]. Degeneration of dopaminergic neuron terminals, especially in the substantia nigra, is a hallmark of Parkinson’s disease[2][6]. While many drugs act at these terminals, the term refers to a compartment, not a specific molecular entity.
Mechanisms generally involve modulation of dopamine synthesis, storage, release, or reuptake at the terminal. Examples: - Blockade of reuptake (e.g., via DAT inhibition by cocaine) - Triggering increased release (e.g., amphetamines) - Precursor supplementation (Levodopa boosts dopamine synthesis in terminals)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dopaminergic neuron terminal.